A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

Steven Attia, Jill Kolesar, Michelle R. Mahoney, Henry C. Pitot, Daniel Laheru, James Heun, Wei Huang, Jens Eickhoff, Charles Erlichman, Kyle D. Holen

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science